Pfizer Expands Santaris Deal to Boost Presence in RNA-Targeted Drug Development
This article was originally published in The Pink Sheet Daily
Executive Summary
RNA-targeted medicines receive a boost from Pfizer's expansion of its strategic alliance with Danish firm Santaris
You may also be interested in...
Santaris, BMS Partner To Develop Therapeutics Targeting miRNA
In the latest of a handful of big pharma RNA partnerships, Bristol-Myers and Santaris have entered into a broad discovery and development deal. For the biotech, it brings a new partner into the string of deals that continue to be its main source of capital.
MicroRNA Momentum Builds, But Will Big Pharma Embrace It?
While interest in microRNA may not be moving at the speed that some investors (and, certainly, some smaller companies) may like, Big Pharma has taken notice of the little oligos and is watching the sector.
Wyeth And Santaris To Collaborate On RNA Antagonists
Danish biotech gets $7 million upfront, $10 million equity investment in Locked Nucleic Acid platform licensing agreement.